Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Arrowhead Pharmaceuticals reports strong fiscal 2024 results and strategic partnerships

Arrowhead Pharmaceuticals' fiscal 2024 performance was robust, fueled by a game-changing partnership with Sarepta and promising results in the cardiometabolic pipeline.
While facing challenges in differentiation and portfolio management, the company's proactive approach and strong financial position present opportunities for growth and innovation.
Strategic collaborations, ongoing Phase III studies, and plans for debt repayment through partnership cash flows underscore Arrowhead's commitment to value creation and sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

New York, New York--(Newsfile Corp. - March 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") (NASDAQ: ARWR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Arrowhead and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arrowhead Pharmaceuticals, Inc. - ARWR

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for mixed dyslipidemia

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or "the Company") (NYSE: ARWR). Investors who purchased Arrowhead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/arwr. The investigation concerns whether Arrowhead and certain of its officers and/or directors have violated federal securities

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals doses first subjects in Phase 1/2 Study of ARO-C3, RNAi therapeutic for treatment of complement mediated diseases

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead presented clinical data on ARO-HIF2 in patients with renal cell carcinoma at 2022 ASCO GU

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

Amkor Technology

BJ`s Wholesale Club Holdings Inc

Crocs

Lattice Semiconductor

MasTec

Performance Food Group

Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.

The Best Russell 2000 Stocks to Buy Before they Rebound

The stock price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) fell by 6.92% in the most recent trading session. This is why it happened.

Arrowhead Pharmaceuticals (ARWR) Stock: Why The Price Fell

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Dr. Christopher Anzalone on Q1 2022 Results - Earnings Call Transcript

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results and hold conference call

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals closes agreement with GlaxoSmithKline for ARO-HSD, RNAi therapeutic for patients with nonalcoholic steatohepatitis (NASH)

Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals will Webcast Fiscal 2022 First Quarter Results on February 2, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results

Arrowhead has major pharma partners for several potential blockbuster therapies. Arrowhead license of ARO-HSD to GSK adds to cash and potential future royalties.

Accumulate Arrowhead For Its RNAi Pipeline

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead initiates Phase 3 PALISADE study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals initiates project to build GMP drug manufacturing facility in the Verona Technology Park in Verona, WI

Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q4 2021 Results - Earnings Call Transcript

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results and hosts a webcast to discuss the year

Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals and GlaxoSmithKline sign exclusive license agreement for RNAi candidate ARO-HSD against NASH

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.

Earnings Outlook For Arrowhead Pharmaceuticals

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead and Janssen collaborating JNJ-75220795 in Development for NASH

Arrowhead Announces JNJ-75220795 in Development for NASH

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection at AASLD Liver Meeting

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Presents Clinical Data on ARO-APOC3 for hypertriglyceridemia at AHA 2021

News for Arrowhead Pharmaceuticals Stock (ARWR)